Active Ingredient History
Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble and stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Diabetes Mellitus, Type 1 (approved 1962)
Autonomic Nervous System Diseases (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Dopamine beta-Hydroxylase (Phase 3)
Fatigue Syndrome, Chronic (Phase 1)
Healthy Volunteers (Phase 1)
Hypertension (Phase 4)
Hypertension, Pregnancy-Induced (Phase 4)
Hypotension, Orthostatic (Phase 3)
Orthostatic Intolerance (Phase 3)
Pre-Eclampsia (Phase 4)
Proteinuria (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue